Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Immunotherapy has changed the way physicians treat cancer patients. This approach to therapy targets the immune system to redirect cells toward the tumor. | Immunology ...

Was it simply a fluke that he kept treating strikingly young patients? Or was his practice one tiny data point in a larger trend? He found his answer after sifting through national health data: ...

The NHS in Scotland has been slammed for failings as women are left to face life endangering waits for surgery.

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...